Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenvatinib in Pediatric Relapsed or Refractory Solid Tumors
2024-512135-80-00Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Jun 2024
- Modality
- Small Molecules
- Countries
- 15
01
Overview
Phase 2, open-label, single-arm trial of lenvatinib in high-grade glioma (HGG), rhabdomyosarcoma (RMS), Ewing sarcoma and 2 more, sponsored by Merck & Co. Primary endpoint: Objective Response Rate at Week 16. Started Jun 2024; status: completed.
02
Drugs
lenvatinib
03
Conditions
high-grade glioma (HGG)rhabdomyosarcoma (RMS)Ewing sarcomaPeripheral Primitive Neuroectodermal Tumor (pPNET)Nonhematologic neoplasms
Beyond the preview
Go deeper on 2024-512135-80-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512135-80-00.